These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35039908)

  • 1. Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant.
    Hibino H; Sakiyama N; Makino Y; Makihara-Ando R; Horinouchi H; Fujiwara Y; Kanda S; Goto Y; Yoshida T; Okuma Y; Shinno Y; Murakami S; Hashimoto H; Akiyoshi T; Imaoka A; Ohe Y; Yamaguchi M; Ohtani H
    Eur J Clin Pharmacol; 2022 Apr; 78(4):613-621. PubMed ID: 35039908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms.
    Oda A; Suzuki Y; Yoshijima C; Sato H; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Itoh H; Ohno K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3648-3658. PubMed ID: 37522799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
    Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
    Diczfalusy U; Nylén H; Elander P; Bertilsson L
    Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
    Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.
    Oda A; Suzuki Y; Sato H; Koyama T; Nakatochi M; Momozawa Y; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Wakai K; Matsuo K; Itoh H; Ohno K
    Clin Transl Sci; 2024 Mar; 17(3):e13768. PubMed ID: 38465776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
    Wu CE; Liaw CC
    Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.
    Takahashi T; Nakamura Y; Tsuya A; Murakami H; Endo M; Yamamoto N
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):653-9. PubMed ID: 21125277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
    Kitazaki T; Fukuda Y; Fukahori S; Oyanagi K; Soda H; Nakamura Y; Kohno S
    Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
    Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L
    Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
    Schmoll HJ; Aapro MS; Poli-Bigelli S; Kim HK; Park K; Jordan K; von Pawel J; Giezek H; Ahmed T; Chan CY
    Ann Oncol; 2006 Jun; 17(6):1000-6. PubMed ID: 16524979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
    Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
    J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
    Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin].
    Sato H; Wada K; Umehara K; Otsu K; Wakamoto A; Hatsuyama T; Fujita A; Sekine K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):733-6. PubMed ID: 23863648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.